ArticleOsteoarthritis and cartilage open2026
CD5L is a potential negative regulator of chondrocyte apoptosis in osteoarthritis.
Article in Osteoarthritis and cartilage open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: CD5 antigen-like (CD5L) protein is a scavenger receptor involved in inflammation control and enriched in the synovial fluid and membranes of osteoarthritis (OA) patients. Although increased CD5L levels have been associated with OA pathology, its direct role in chondrocytes and contribution to cartilage degeneration remain unknown. We investigated the impact of CD5L on human chondrocytes in the context of OA. Methods: We compared CD5L mRNA levels in primary chondrocytes between OA patients and unaffected controls. We also measured CD5L levels in two chondrocyte cell lines under conditions mimicking OA. RNAseq was performed to determine the effects of increasing CD5L expression on the chondrocyte transcriptome. Finally, we studied the influence of CD5L levels on chondrocyte survival by depleting or overexpressing CD5L in chondrocyte cell lines. Results: CD5L transcript levels were higher in primary chondrocytes from OA patients than in those from controls. Treatment with the pro-inflammatory cytokine IL1β or doxorubicin further induced CD5L expression in primary and cultured chondrocytes. Transcriptomic analysis revealed a correlation between high CD5L transcript levels and expression of genes involved in programmed cell death, inflammation, and differentiation. CD5L knockout increased survival of doxorubicin-treated chondrocytes and reduced apoptosis marker levels compared to non-targeting controls. Conclusion: Our data indicate that CD5L plays an important role in regulating chondrocyte cell death. CD5L expression levels are high in chondrocytes from OA patients, and decreasing CD5L expression reduces chondrocyte apoptosis induction
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.